- Home
- AEI vs BMEA Comparison
AEI vs BMEA Comparison
Compare AEI & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEI
- BMEA
- Stock Information
- Founded
- AEI 2014
- BMEA 2017
- Country
- AEI United States
- BMEA United States
- Employees
- AEI N/A
- BMEA N/A
- Industry
- AEI Building operators
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- AEI Real Estate
- BMEA Health Care
- Exchange
- AEI Nasdaq
- BMEA Nasdaq
- Market Cap
- AEI 124.7M
- BMEA 125.0M
- IPO Year
- AEI N/A
- BMEA 2021
- Fundamental
- Price
- AEI $2.81
- BMEA $1.44
- Analyst Decision
- AEI
- BMEA Strong Buy
- Analyst Count
- AEI 0
- BMEA 8
- Target Price
- AEI N/A
- BMEA $10.63
- AVG Volume (30 Days)
- AEI 84.2K
- BMEA 3.6M
- Earning Date
- AEI 11-13-2025
- BMEA 10-29-2025
- Dividend Yield
- AEI N/A
- BMEA N/A
- EPS Growth
- AEI N/A
- BMEA N/A
- EPS
- AEI N/A
- BMEA N/A
- Revenue
- AEI $16,069,911.00
- BMEA N/A
- Revenue This Year
- AEI N/A
- BMEA N/A
- Revenue Next Year
- AEI N/A
- BMEA N/A
- P/E Ratio
- AEI N/A
- BMEA N/A
- Revenue Growth
- AEI 74.28
- BMEA N/A
- 52 Week Low
- AEI $0.70
- BMEA $1.29
- 52 Week High
- AEI $4.55
- BMEA $12.85
- Technical
- Relative Strength Index (RSI)
- AEI 57.78
- BMEA 37.97
- Support Level
- AEI $2.35
- BMEA $1.34
- Resistance Level
- AEI $2.61
- BMEA $1.71
- Average True Range (ATR)
- AEI 0.23
- BMEA 0.14
- MACD
- AEI -0.03
- BMEA -0.05
- Stochastic Oscillator
- AEI 63.93
- BMEA 12.02
About AEI Alset Inc. (TX)
Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.